NFXF Blog
Featured
The initiative will build on our 40 years of work, promoting broader use of evidence-based information among individuals with FXS, caregivers, family members, community partners, and healthcare providers nationwide.
Why Fragile X Syndrome Treatment Information Feels So Confusing
08 mins read
FXS Tips & Support for Traveling + Free Downloads
06 mins read
Advocacy is Year-Round: What That Looks Like
05 mins read
Understanding What the Texas v. Kennedy Ruling Means for Community Living
03 mins read
All Articles
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] We have experienced a setback with the cancellation of the extension phase of the STX209 drug trials for Fragile X syndrome, and what have been deemed the technical failures of two other ongoing trials of this drug.
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] By now, many of you have heard that Seaside Therapeutics has decided to end the extension of the trial medication Arbaclofen (STX209).